Monsanto estenderá as aprovações de exportação do RR1
13 de julho de 2010 ST. LOUIS, Missouri, EUA — Monsanto has announced in a press release that it will extend its regulatory commitment for its Roundup Ready (RR1) soybean patent through 2021, originally set to expire in 2014 with continuing global regulatory approvals through 2017. Soybean breeders and seed companies with development and marketing rights that run through patent expiration are in a position to offer RR1 seeds as a generic product beginning in 2015.
Monsanto is taking steps for an orderly transition of the technology to the public domain; upon expiration of the RR1 patents the technology will be able to be used by seed companies and their farmer customers without making royalty payments to Monsanto.
By maintaining the Roundup Ready soybean regulatory approvals in other countries through 2021, farmers planting the technology post-patent will continue to have access to broadly market their grain, Monsanto says. It also gives farmers and the industry more than a decade to develop plans and mechanisms to assure continuing import approval support in export markets beyond 2021. The company says this extension is one more step to assist the industry in the creation of a long-term solution to the question of providing regulatory support. The first-generation Roundup Ready soybean technology is the first of
several technologies developed by Monsanto and other trait providers that will be coming off patent within the next decade.
Monsanto says it will not use the patents to prevent US farmers from saving RR1 soybeans to plant on their own farms, and will not limit the ability of breeding collaborators to enforce their property rights in varieties that are the product of Monsanto collaborations with other companies. Biotech trait developers that want to develop new, proprietary (patented) stacks with the RR1 trait have a route to market that permits development of those stacks prior to expiration of the RR1 patents, says the company. For all stacks other than those involving another glyphosate tolerance event, Monsanto has already enabled multiple channels for on-patent development and commercialization of stacks with the RR1 event (e.g., stacks with other herbicide tolerance genes or with oil quality genes). In the case of a glyphosate-on-glyphosate stack (with Optimum GAT/RR1 being the only example), Monsanto has recently offered DuPont a license to develop the Optimum GAT/RR1 stack prior to patent expiration with discounted royalties on RR1.
Receba a Newsletter hoje mesmo!
